基于生物标志物的精密治疗阿尔茨海默病:多维证据导致个性化医学的新突破
Anastasia Bougea1, Philippos Gourzis2
11st Department of Neurology, National and Kapodistrian University of Athens, 15772 Athens, Greece.
Journal of clinical medicine
|August 29, 2024
概括
精准医学和生物标志物为阿尔茨海默病 (AD) 提供了新的希望. 先进的诊断,如遗传风险评分和液体生物标志物,有望更早地检测和个性化治疗AD.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 生物化学 生物化学
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,其特征是蛋白质的异常积累和认知能力的下降.
- 目前对阿尔茨海默病的治疗主要是症状性的,只能提供暂时的缓解.
- 对阿尔茨海默病有效的诊断和治疗策略有极大的需要.
研究的目的:
- 审查针对阿尔茨海默病的精准医学最新进展.
- 探索新生物标志物在阿尔茨海默病的诊断和治疗中的作用.
- 突出这些进步的潜力来彻底改变AD护理.
主要方法:
- 在PubMed上进行了全面的文献搜索,使用与AD,生物标志物和精密医学相关的特定MeSH术语.
- 关键的搜索词包括"阿尔茨海默病"",生物标志物"",APOE"",APP"",GWAS"",脑脊液"",多基因风险评分"",Aβ42"",τP-181"",p-tau217"",ptau231"",蛋白质学"",总蛋白"和"精准医学".
- 用布尔运算符来改进搜索策略.
主要成果:
- 全基因组关联研究 (GWAS) 已经确定了AD的众多遗传风险变异.
- 转录组分析揭示了AD大脑中基因表达模式的改变.
- 蛋白质组,代谢组和神经影像分析确定了血液,尿液和脑脊液中的潜在生物标志物,用于早期AD诊断和进展监测.
结论:
- 将各种生物标志物与超敏感免疫测试,质谱和代谢学等先进技术相结合,正在推动AD研究.
- 这些综合方法为阿尔茨海默病患者个性化医疗保健策略铺平了道路.
- 正在通过精准医学彻底改变阿尔茨海默病的诊断和治疗方面取得重大进展.
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
Alzheimer's Disease: Overview
454
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
454


